A microbiological revolution meets an ancient disease: Improving the management of tuberculosis with genomics

Clinical Microbiology Reviews

Volumn 28, Issue 2, 2015, Pages 523-539

  Wlodarska, Marta ^a,b   Johnston, James C ^c,d   Gardy, Jennifer L ^c,d   Tang, Patrick ^c,d  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; GENOMIC DNA; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENOME; BACTERIUM IDENTIFICATION; COLONY FORMING UNIT; DISEASE TRANSMISSION; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOMICS; HUMAN; MICROBIOME; MIXED INFECTION; MOLECULAR EPIDEMIOLOGY; MUTATION RATE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TUBERCULOSIS; VARIABLE NUMBER OF TANDEM REPEAT; GENETICS; HOST PATHOGEN INTERACTION; MICROBIOLOGY; MUTATION; TRANSMISSION;

MYCOBACTERIUM TUBERCULOSIS;

DRUG RESISTANCE, BACTERIAL; GENOMICS; HOST-PATHOGEN INTERACTIONS; HUMANS; MOLECULAR EPIDEMIOLOGY; MUTATION; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84925779490     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00124-14     Document Type: Article

References (106)

1. WHO. 2013. Global tuberculosis report 2013. WHO, Geneva, Switzerland.
2. Comas I, Coscolla M, Luo T, Borrell S, Holt KE, Kato-Maeda M, Parkhill J, Malla B, Berg S, Thwaites G, Yeboah-Manu D, Bothamley G, Mei J, Wei L, Bentley S, Harris SR, Niemann S, Diel R, Aseffa A, Gao Q, Young D, Gagneux S. 2013. Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat Genet 45:1176-1182. http://dx.doi.org/10.1038/ng.2744.
3. Brosch R, Gordon SV, Marmiesse M, Brodin P, Buchrieser C, Eiglmeier K, Garnier T, Gutierrez C, Hewinson G, Kremer K, Parsons LM, Pym AS, Samper S, van Soolingen D, Cole ST. 2002. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci U S A 99:3684-3689. http://dx.doi.org/10.1073/pnas .052548299.
4. Bos KI, Harkins KM, Herbig A, Coscolla M, Weber N, Comas I, Forrest SA, Bryant JM, Harris SR, Schuenemann VJ, Campbell TJ, Majander K, Wilbur AK, Guichon RA, Wolfe Steadman DL, Cook DC, Niemann S, Behr MA, Zumarraga M, Bastida R, Huson D, Nieselt K, Young D, Parkhill J, Buikstra JE, Gagneux S, Stone AC, Krause J. 2014. Pre-Columbian mycobacterial genomes reveal seals as a source of New World human tuberculosis. Nature 514:494-497. http://dx.doi.org/10 .1038/nature13591.
5. Mehta JB, Dutt A, Harvill L, Mathews KM. 1991. Epidemiology of extrapulmonary tuberculosis. a comparative analysis with pre-AIDS era. Chest J 99:1134-1138. http://dx.doi.org/10.1378/chest.99.5.1134.
6. Zumla A, Raviglione M, Hafner R, von Reyn CF. 2013. Tuberculosis. N Engl J Med 368:745-755. http://dx.doi.org/10.1056/NEJMra1200894.
7. Raviglione M, Marais B, Floyd K, Lönnroth K, Getahun H, Migliori GB, Harries AD, Nunn P, Lienhardt C, Graham S, Chakaya J, Weyer K, Cole S, Kaufmann SH, Zumla A. 2012. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 379:1902-1913. http://dx.doi.org/10.1016/S0140-6736(12)60727-2.
8. Supply P, Marceau M, Mangenot S, Roche D, Rouanet C, Khanna V, Majlessi L, Criscuolo A, Tap J, Pawlik A, Fiette L, Orgeur M, Fabre M, Parmentier C, Frigui W, Simeone R, Boritsch EC, Debrie A-S, Willery E, Walker D, Quail MA, Ma L, Bouchier C, Salvignol G, Sayes F, Cascioferro A, Seemann T, Barbe V, Locht C, Gutierrez M-C, Leclerc C, Bentley SD, Stinear TP, Brisse S, Médigue C, Parkhill J, Cruveiller S, Brosch R. 2013. Genomic analysis of smooth tubercle bacilli provides insights into ancestry and pathoadaptation of Mycobacterium tuberculosis. Nat Genet 45:172-179. http://dx.doi.org/10.1038/ng.2517.
9. Boritsch EC, Supply P, Honoré N, Seeman T, Stinear TP, Brosch R. 2014. A glimpse into the past and predictions for the future: the molecular evolution of the tuberculosis agent. Mol Microbiol 93:835-852. http://dx.doi.org/10.1111/mmi.12720.
10. Van Soolingen D, van der Zanden AG, de Haas PE, Noordhoek GT, Kiers A, Foudraine NA, Portaels F, Kolk AH, Kremer K, van Embden JD. 1998. Diagnosis of Mycobacterium microti infections among humans by using novel genetic markers. J Clin Microbiol 36:1840-1845.
11. Rodríguez E, Sánchez LP, Pérez S, Herrera L, Jiménez MS, Samper S, Iglesias MJ. 2009. Human tuberculosis due to Mycobacterium bovis and M. caprae in Spain, 2004-2007. Int J Tuberc Lung Dis 13:1536-1541.
12. Van Ingen J, Rahim Z, Mulder A, Boeree MJ, Simeone R, Brosch R, van Soolingen D. 2012. Characterization of Mycobacterium orygis as M. tuberculosis complex subspecies. Emerg Infect Dis 18:653-655. http://dx .doi.org/10.3201/eid1804.110888.
13. Kiers A, Klarenbeek A, Mendelts B, Van Soolingen D, Koëter G. 2008. Transmission of Mycobacterium pinnipedii to humans in a zoo with marine mammals. Int J Tuberc Lung Dis 12:1469-1473.
14. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream M-A, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537-544. http://dx.doi.org/10.1038 /31159.
15. Mostowy S, Behr MA. 2005. The origin and evolution of Mycobacterium tuberculosis. Clin Chest Med 26:207-216. http://dx.doi.org/10.1016/j .ccm.2005.02.004.
16. Coscolla M, Gagneux S. 2010. Does M. tuberculosis genomic diversity explain disease diversity? Drug Discov Today Dis Mech 7:e43- e59. http: //dx.doi.org/10.1016/j.ddmec.2010.09.004.
17. Tortoli E. 2014. Microbiological features and clinical relevance of new species of the genus Mycobacterium. Clin Microbiol Rev 27:727-752. http://dx.doi.org/10.1128/CMR.00035-14.
18. Liu L, Li Y, Li S, Hu N, He Y, Pong R, Lin D, Lu L, Law M. 2012. Comparison of next-generation sequencing systems. J Biomed Biotechnol 2012:251364. http://dx.doi.org/10.1155/2012/251364.
19. Didelot X, Bowden R, Wilson DJ, Peto TEA, Crook DW. 2012. Transforming clinical microbiology with bacterial genome sequencing. Nat Rev Genet 13:601-612. http://dx.doi.org/10.1038/nrg3226.
20. Yin X, Zheng L, Lin L, Hu Y, Zheng F, Hu Y, Wang Q. 2013. Commercial MPT64-based tests for rapid identification of Mycobacterium tuberculosis complex: a meta-analysis. J Infect 67:369-377. http: //dx.doi.org/10.1016/j.jinf.2013.06.009.
21. Roberts SA, Lowe O, Pandey S, Williamson DA, Newton S, Vaughan R. 2012. Comparison of the MGIT TBc immunochromatographic assay with the Accuprobe Gen-Probe TB assay for identification of Mycobacterium tuberculosis complex: results from a low-burden tuberculosis setting. Diagn Microbiol Infect Dis 74:415-416. http://dx.doi.org/10.1016 /j.diagmicrobio.2012.08.007.
22. Scott LE, McCarthy K, Gous N, Nduna M, Van Rie A, Sanne I, Venter WF, Duse A, Stevens W. 2011. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med 8:e1001061. http://dx.doi.org/10.1371/journal.pmed.1001061.
23. McNabb A, Adie K, Rodrigues M, Black WA, Isaac-Renton J. 2006. Direct identification of mycobacteria in primary liquid detection media by partial sequencing of the 65-kilodalton heat shock protein gene. J Clin Microbiol 44:60-66. http://dx.doi.org/10.1128/JCM.44.1.60-66.2006.
24. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, Kop J, Owens MR, Rodgers R, Banada P, Safi H, Blakemore R, Lan NTN, Jones- López EC, Levi M, Burday M, Ayakaka I, Mugerwa RD, McMillan B, Winn-Deen E, Christel L, Dailey P, Perkins MD, Persing DH, Alland D. 2010. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 48:229-237. http://dx.doi.org/10.1128/JCM.01463-09.
25. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD. 2010. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363:1005-1015. http://dx.doi.org /10.1056/NEJMoa0907847.
26. Walusimbi S, Bwanga F, De Costa A, Haile M, Joloba M, Hoffner S. 2013. Meta-analysis to compare the accuracy of GeneXpert, MODS and the WHO 2007 algorithm for diagnosis of smear-negative pulmonary tuberculosis. BMC Infect Dis 13:507. http://dx.doi.org/10.1186/1471 -2334-13-507.
27. Albert H, Ademun PJ, Lukyamuzi G, Nyesiga B, Manabe Y, Joloba M, Wilson S, Perkins MD. 2011. Feasibility of magnetic bead technology for concentration of mycobacteria in sputum prior to fluorescence microscopy. BMC Infect Dis 11:125. http://dx.doi.org/10.1186/1471-2334 -11-125.
28. Ghodbane R, Drancourt M. 2013. Magnetic bead protocol for culturing Mycobacterium tuberculosis from sputum specimens. J Clin Microbiol 51:1578-1579. http://dx.doi.org/10.1128/JCM.03428-12.
29. Liu J, Sun Z-Q, Pei H, Zhang S-L, Zhang S-L, Wilson S, De Smet K, Cerullakandiyil N, Thayyullathil T, AL-Suwaidi Z, Song Y-Z. 2013. Increased case finding of tuberculosis from sputum and sputum deposits after magnetic bead concentration of mycobacteria. J Microbiol Methods 93:144-147. http://dx.doi.org/10.1016/j.mimet.2013.02.010.
30. Elitas M, Martinez-Duarte R, Dhar N, McKinney JD, Renaud P. 2014. Dielectrophoresis-based purification of antibiotic-treated bacterial subpopulations. Lab Chip 14:1850 -1857. http://dx.doi.org/10 .1039/C4LC00109E.
31. Wang S, Inci F, De Libero G, Singhal A, Demirci U. 2013. Point-ofcare assays for tuberculosis: role of nanotechnology/microfluidics. Biotechnol Adv 31:438-449. http://dx.doi.org/10.1016/j.biotechadv.2013 .01.006.
32. Doughty EL, Sergeant MJ, Adetifa I, Antonio M, Pallen MJ. 2014. Culture-independent detection and characterisation of Mycobacterium tuberculosis and M. africanum in sputum samples using shotgun metagenomics on a benchtop sequencer. PeerJ 2:e585. http://dx.doi.org/10 .7717/peerj.585.
33. Branton D, Deamer DW, Marziali A, Bayley H, Benner SA, Butler T, Di Ventra M, Garaj S, Hibbs A, Huang X, Jovanovich SB, Krstic PS, Lindsay S, Ling XS, Mastrangelo CH, Meller A, Oliver JS, Pershin YV, Ramsey JM, Riehn R, Soni GV, Tabard-Cossa V, Wanunu M, Wiggin M, Schloss JA. 2008. The potential and challenges of nanopore sequencing. Nat Biotechnol 26:1146-1153. http://dx.doi.org/10.1038/nbt.1495.
34. Macaulay IC, Voet T. 2014. Single cell genomics: advances and future perspectives. PLoS Genet 10:e1004126. http://dx.doi.org/10.1371/journal .pgen.1004126.
35. Ling DI, Zwerling AA, Pai M. 2008. Rapid diagnosis of drug-resistant TB using line probe assays: from evidence to policy. Expert Rev Respir Med 2:583-588. http://dx.doi.org/10.1586/17476348.2.5.583.
36. Rossau R, Traore H, De Beenhouwer H, Mijs W, Jannes G, De Rijk P, Portaels F. 1997. Evaluation of the INNO-LiPA Rif.TB assay, a reverse hybridization assay for the simultaneous detection of Mycobacterium tuberculosis complex and its resistance to rifampin. Antimicrob Agents Chemother 41:2093-2098.
37. Hillemann D, Rüsch-Gerdes S, Richter E. 2007. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 45:2635-2640. http://dx.doi.org/10.1128/JCM.00521-07.
38. Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, Hooks DP, Cowan LS, Plikaytis BB, Posey JE. 2011. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 55:2032-2041. http://dx.doi.org/10.1128/AAC.01550-10.
39. Zhang H, Li D, Zhao L, Fleming J, Lin N, Wang T, Liu Z, Li C, Galwey N, Deng J, Zhou Y, Zhu Y, Gao Y, Wang T, Wang S, Huang Y, Wang M, Zhong Q, Zhou L, Chen T, Zhou J, Yang R, Zhu G, Hang H, Zhang J, Li F, Wan K, Wang J, Zhang X-E, Bi L. 2013. Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance. Nat Genet 45:1255-1260. http://dx.doi.org/10.1038/ng.2735.
40. Farhat MR, Shapiro BJ, Kieser KJ, Sultana R, Jacobson KR, Victor TC, Warren RM, Streicher EM, Calver A, Sloutsky A, Kaur D, Posey JE, Plikaytis B, Oggioni MR, Gardy JL, Johnston JC, Rodrigues M, Tang PKC, Kato-Maeda M, Borowsky ML, Muddukrishna B, Kreiswirth BN, Kurepina N, Galagan J, Gagneux S, Birren B, Rubin EJ, Lander ES, Sabeti PC, Murray M. 2013. Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nat Genet 45:1183-1189. http://dx.doi.org/10.1038/ng.2747.
41. Safi H, Lingaraju S, Amin A, Kim S, Jones M, Holmes M, McNeil M, Peterson SN, Chatterjee D, Fleischmann R, Alland D. 2013. Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl-_-D-arabinose biosynthetic and utilization pathway genes. Nat Genet 45:1190-1197. http://dx.doi.org/10 .1038/ng.2743.
42. Casali N, Nikolayevskyy V, Balabanova Y, Harris SR, Ignatyeva O, Kontsevaya I, Corander J, Bryant J, Parkhill J, Nejentsev S, Horstmann RD, Brown T, Drobniewski F. 2014. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat Genet 46: 279-286. http://dx.doi.org/10.1038/ng.2878.
43. Eldholm V, Norheim G, von der Lippe B, Kinander W, Dahle UR, Caugant DA, Mannsåker T, Mengshoel AT, Dyrhol-Riise AM, Balloux F. 2014. Evolution of extensively drug-resistant Mycobacterium tuberculosis from a susceptible ancestor in a single patient. Genome Biol 15:490. http://dx.doi.org/10.1186/s13059-014-0490-3.
44. Andries K, Verhasselt P, Guillemont J, Göhlmann HWH, Neefs J-M, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223-227. http://dx .doi.org/10.1126/science.1106753.
45. Clark TG, Mallard K, Coll F, Preston M, Assefa S, Harris D, Ogwang S, Mumbowa F, Kirenga B, O'Sullivan DM, Okwera A, Eisenach KD, Joloba M, Bentley SD, Ellner JJ, Parkhill J, Jones-López EC, McNerney R. 2013. Elucidating emergence and transmission of multidrug-resistant tuberculosis in treatment experienced patients by whole genome sequencing. PLoS One 8:e83012. http://dx.doi.org/10.1371/journal.pone .0083012.
46. De Vos M, Muller B, Borrell S, Black PA, van Helden PD, Warren RM, Gagneux S, Victor TC. 2013. Putative compensatory mutations in the rpoC gene of rifampin-resistant Mycobacterium tuberculosis are associated with ongoing transmission. Antimicrob Agents Chemother 57:827-832. http://dx.doi.org/10.1128/AAC.01541-12.
47. Brandis G, Hughes D. 2013. Genetic characterization of compensatory evolution in strains carrying rpoB Ser531Leu, the rifampicin resistance mutation most frequently found in clinical isolates. J Antimicrob Chemother 68:2493-2497. http://dx.doi.org/10.1093/jac/dkt224.
48. Comas I, Borrell S, Roetzer A, Rose G, Malla B, Kato-Maeda M, Galagan J, Niemann S, Gagneux S. 2012. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet 44:106-110. http://dx.doi.org/10.1038/ng.1038.
49. Aguilar D, Hanekom M, Mata D, Gey van Pittius NC, van Helden PD, Warren RM, Hernandez-Pando R. 2010. Mycobacterium tuberculosis strains with the Beijing genotype demonstrate variability in virulence associated with transmission. Tuberculosis (Edinb) 90:319-325. http: //dx.doi.org/10.1016/j.tube.2010.08.004.
50. Reiling N, Homolka S, Walter K, Brandenburg J, Niwinski L, Ernst M, Herzmann C, Lange C, Diel R, Ehlers S, Niemann S. 2013. Cladespecific virulence patterns of Mycobacterium tuberculosis complex strains in human primary macrophages and aerogenically infected mice. mBio 4:e00250-13. http://dx.doi.org/10.1128/mBio.00250-13.
51. Ford CB, Shah RR, Maeda MK, Gagneux S, Murray MB, Cohen T, Johnston JC, Gardy J, Lipsitch M, Fortune SM. 2013. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet 45:784-790. http://dx.doi.org/10.1038/ng.2656.
52. Trauner A, Borrell S, Reither K, Gagneux S. 2014. Evolution of drug resistance in tuberculosis: recent progress and implications for diagnosis and therapy. Drugs 74:1063-1072. http://dx.doi.org/10.1007 /s40265-014-0248-y.
53. Köser CU, Bryant JM, Becq J, Török ME, Ellington MJ, Marti-Renom MA, Carmichael AJ, Parkhill J, Smith GP, Peacock SJ. 2013. Wholegenome sequencing for rapid susceptibility testing of M. tuberculosis. N Engl J Med 369:290-292. http://dx.doi.org/10.1056/NEJMc1215305.
54. Kim SJ. 2005. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J 25:564-569. http://dx.doi.org/10.1183 /09031936.05.00111304.
55. Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, Cambau E, Aubry A. 2012. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 67:819-831. http://dx.doi.org/10.1093/jac/dkr566.
56. Laurenzo D, Mousa SA. 2011. Mechanisms of drug resistance in Mycobacterium tuberculosis and current status of rapid molecular diagnostic testing. Acta Trop 119:5-10. http://dx.doi.org/10.1016/j.actatropica.2011.04 .008.
57. Shafer RW. 2006. Rationale and uses of a public HIV drug-resistance database. J Infect Dis 194(Suppl 1):S51-S58. http://dx.doi.org/10.1086 /505356.
58. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. 2009. Tuberculosis drug resistance mutation database. PLoS Med 6:e2. http://dx.doi.org/10.1371/journal.pmed.1000002.
59. Flandrois J-P, Lina G, Dumitrescu O. 2014. MUBII-TB-DB: a database of mutations associated with antibiotic resistance in Mycobacterium tuberculosis. BMC Bioinformatics 15:107. http://dx.doi.org/10.1186/1471 -2105-15-107.
60. Kasaie P, Andrews JR, Kelton WD, Dowdy DW. 2014. Timing of tuberculosis transmission and the impact of household contact tracing. An agent-based simulation model. Am J Respir Crit Care Med 189:845-852. http://dx.doi.org/10.1164/rccm.201310-1846OC.
61. Shrivastava SR, Shrivastava PS, Ramasamy J. 2014. Assessing the utility of contact tracing in reducing the magnitude of tuberculosis. Infect Ecol Epidemiol 4:10.3402/iee.v4.25265. http://dx.doi.org/10 .3402/iee.v4.25265.
62. Gardy JL, Johnston JC, Sui SJH, Cook VJ, Shah L, Brodkin E, Rempel S, Moore R, Zhao Y, Holt R, Varhol R, Birol I, Lem M, Sharma MK, Elwood K, Jones SJM, Brinkman FSL, Brunham RC, Tang P. 2011. Whole-genome sequencing and social-network analysis of a tuberculosis outbreak. N Engl J Med 364:730 -739. http://dx .doi.org/10.1056/NEJMoa1003176.
63. Walker TM, Ip CLC, Harrell RH, Evans JT, Kapatai G, Dedicoat MJ, Eyre DW, Wilson DJ, Hawkey PM, Crook DW, Parkhill J, Harris D, Walker AS, Bowden R, Monk P, Smith EG, Peto TEA. 2013. Wholegenome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study. Lancet Infect Dis 13:137-146. http: //dx.doi.org/10.1016/S1473-3099(12)70277-3.
64. Streicher EM, Victor TC, van der Spuy G, Sola C, Rastogi N, van Helden PD, Warren RM. 2007. Spoligotype signatures in the Mycobacterium tuberculosis complex. J Clin Microbiol 45:237-240. http://dx.doi .org/10.1128/JCM.01429-06.
65. Supply P, Allix C, Lesjean S, Cardoso-Oelemann M, Rüsch-Gerdes S, Willery E, Savine E, de Haas P, van Deutekom H, Roring S, Bifani P, Kurepina N, Kreiswirth B, Sola C, Rastogi N, Vatin V, Gutierrez MC, Fauville M, Niemann S, Skuce R, Kremer K, Locht C, van Soolingen D. 2006. Proposal for standardization of optimized mycobacterial interspersed repetitive-unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol 44:4498-4510. http://dx.doi.org /10.1128/JCM.01392-06.
66. Torrea G, Levee G, Grimont P, Martin C, Chanteau S, Gicquel B. 1995. Chromosomal DNA fingerprinting analysis using the insertion sequence IS6110 and the repetitive element DR as strain-specific markers for epidemiological study of tuberculosis in French Polynesia. J Clin Microbiol 33:1899-1904.
67. Köser CU, Ellington MJ, Cartwright EJP, Gillespie SH, Brown NM, Farrington M, Holden MTG, Dougan G, Bentley SD, Parkhill J, Peacock SJ. 2012. Routine use of microbial whole genome sequencing in diagnostic and public health microbiology. PLoS Pathog 8:e1002824. http://dx.doi.org/10.1371/journal.ppat.1002824.
68. Sola C, Filliol I, Legrand E, Lesjean S, Locht C, Supply P, Rastogi N. 2003. Genotyping of the Mycobacterium tuberculosis complex using MIRUs: association with VNTR and spoligotyping for molecular epidemiology and evolutionary genetics. Infect Genet Evol 3:125-133. http: //dx.doi.org/10.1016/S1567-1348(03)00011-X.
69. Niemann S, Köser CU, Gagneux S, Plinke C, Homolka S, Bignell H, Carter RJ, Cheetham RK, Cox A, Gormley NA, Kokko-Gonzales P, Murray LJ, Rigatti R, Smith VP, Arends FPM, Cox HS, Smith G, Archer JAC. 2009. Genomic diversity among drug sensitive and multidrug resistant isolates of Mycobacterium tuberculosis with identical DNA fingerprints. PLoS One 4:e7407. http://dx.doi.org/10.1371/journal.pone .0007407.
70. Schurch AC, Kremer K, Daviena O, Kiers A, Boeree MJ, Siezen RJ, van Soolingen D. 2010. High-resolution typing by integration of genome sequencing data in a large tuberculosis cluster. J Clin Microbiol 48:3403-3406. http://dx.doi.org/10.1128/JCM.00370-10.
71. Roetzer A, Diel R, Kohl TA, Rückert C, Nübel U, Blom J, Wirth T, Jaenicke S, Schuback S, Rüsch-Gerdes S, Supply P, Kalinowski J, Niemann S. 2013. Whole genome sequencing versus traditional genotyping for investigation of a Mycobacterium tuberculosis outbreak: a longitudinal molecular epidemiological study. PLoSMed10:e1001387. http: //dx.doi.org/10.1371/journal.pmed.1001387.
72. Kato-Maeda M, Ho C, Passarelli B, Banaei N, Grinsdale J, Flores L, Anderson J, Murray M, Rose G, Kawamura LM, Pourmand N, Tariq MA, Gagneux S, Hopewell PC. 2013. Use of whole genome sequencing to determine the microevolution of Mycobacterium tuberculosis during an outbreak. PLoS One 8:e58235. http://dx.doi.org/10.1371/journal .pone.0058235.
73. Luo T, Yang C, Peng Y, Lu L, Sun G, Wu J, Jin X, Hong J, Li F, Mei J, DeRiemer K, Gao Q. 2014. Whole-genome sequencing to detect recent transmission of Mycobacterium tuberculosis in settings with a high burden of tuberculosis. Tuberculosis (Edinb) 94:434-440. http://dx.doi .org/10.1016/j.tube.2014.04.005.
74. Jamieson FB, Teatero S, Guthrie JL, Neemuchwala A, Fittipaldi N, Mehaffy C. 2014. Whole-genome sequencing of the Mycobacterium tuberculosis Manila sublineage results in less clustering and better resolution than mycobacterial interspersed repetitive-unit-variable-number tandem-repeat (MIRU-VNTR) typing and spoligotyping. J Clin Microbiol 52:3795-3798. http://dx.doi.org/10.1128/JCM.01726-14.
75. Mehaffy C, Guthrie JL, Alexander DC, Stuart R, Rea E, Jamieson FB. 2014. Marked microevolution of a unique Mycobacterium tuberculosis strain in 17 years of ongoing transmission in a high risk population. PLoS One 9:e112928. http://dx.doi.org/10.1371/journal.pone.0112928.
76. Stucki D, Ballif M, Bodmer T, Coscolla M, Maurer A-M, Droz S, Butz C, Borrell S, Längle C, Feldmann J, Furrer H, Mordasini C, Helbling P, Rieder HL, Egger M, Gagneux S, Fenner L. 30 October 2014. Tracking a tuberculosis outbreak over 21 years: strain-specific singlenucleotide polymorphism typing combined with targeted wholegenome sequencing. J Infect Dis http://dx.doi.org/10.1093/infdis/jiu601.
77. Schürch AC, Kremer K, Kiers A, Daviena O, Boeree MJ, Siezen RJ, Smith NH, van Soolingen D. 2010. The tempo and mode of molecular evolution of Mycobacterium tuberculosis at patient-to-patient scale. Infect Genet Evol 10:108-114. http://dx.doi.org/10.1016/j.meegid.2009.10 .002.
78. Török ME, Reuter S, Bryant J, Köser CU, Stinchcombe SV, Nazareth B, Ellington MJ, Bentley SD, Smith GP, Parkhill J, Peacock SJ. 2013. Rapid whole-genome sequencing for investigation of a suspected tuberculosis outbreak. J Clin Microbiol 51:611-614. http://dx.doi.org/10 .1128/JCM.02279-12.
79. Walker TM, Lalor MK, Broda A, Ortega LS, Morgan M, Parker L, Churchill S, Bennett K, Golubchik T, Giess AP, Del Ojo Elias C, Jeffery KJ, Bowler ICJW, Laurenson IF, Barrett A, Drobniewski F, McCarthy ND, Anderson LF, Abubakar I, Thomas HL, Monk P, Smith EG, Walker AS, Crook DW, Peto TEA, Conlon CP. 2014. Assessment of Mycobacterium tuberculosis transmission in Oxfordshire, UK, 2007-12, with whole pathogen genome sequences: an observational study. Lancet Respir Med 2:285-292. http://dx.doi.org/10.1016/S2213-2600(14)70027-X.
80. Didelot X, Gardy J, Colijn C. 2014. Bayesian inference of infectious disease transmission from whole-genome sequence data. Mol Biol Evol 31:1869-1879. http://dx.doi.org/10.1093/molbev/msu121.
81. Kohl TA, Diel R, Harmsen D, Rothgänger J, Meywald Walter K, Merker M, Weniger T, Niemann S. 2014. Whole genome based Mycobacterium tuberculosis surveillance: a standardized, portable and expandable approach. J Clin Microbiol 52:2479-2486. http://dx.doi.org/10 .1128/JCM.00567-14.
82. Coll F, Mallard K, Preston MD, Bentley S, Parkhill J, McNerney R, Martin N, Clark TG. 2012. SpolPred: rapid and accurate prediction of Mycobacterium tuberculosis spoligotypes from short genomic sequences. Bioinformatics 28:2991-2993. http://dx.doi.org/10.1093/bioinformatics /bts544.
83. Halachev MR, Chan JZ-M, Constantinidou CI, Cumley N, Bradley C, Smith-Banks M, Oppenheim B, Pallen MJ. 2014. Genomic epidemiology of a protracted hospital outbreak caused by multidrug-resistant Acinetobacter baumannii in Birmingham, England. Genome Med 6:70. http://dx.doi.org/10.1186/s13073-014-0070-x.
84. Snitkin ES, Zelazny AM, Thomas PJ, Stock F, NISC Comparative Sequencing Program Group, Henderson DK, Palmore TN, Segre JA. 2012. Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. Sci Transl Med 4:148-116. http://dx.doi.org/10.1126/scitranslmed.3004129.
85. Colijn C, Gardy J. 2014. Phylogenetic tree shapes resolve disease transmission patterns. Evol Med Public Health 2014:96-108. http://dx.doi .org/10.1093/emph/eou018.
86. Bryant JM, Harris SR, Parkhill J, Dawson R, Diacon AH, van Helden P, Pym A, Mahayiddin AA, Chuchottaworn C, Sanne IM, Louw C, Boeree MJ, Hoelscher M, McHugh TD, Bateson ALC, Hunt RD, Mwaigwisya S, Wright L, Gillespie SH, Bentley SD. 2013. Wholegenome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study. Lancet Respir Med 1:786-792. http://dx.doi.org/10.1016/S2213-2600(13)70231-5.
87. Ford CB, Lin PL, Chase MR, Shah RR, Iartchouk O, Galagan J, Mohaideen N, Ioerger TR, Sacchettini JC, Lipsitch M, Flynn JL, Fortune SM. 2011. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet 43:482-486. http://dx.doi.org/10.1038/ng.811.
88. Bryant JM, Schürch AC, van Deutekom H, Harris SR, de Beer JL, de Jager V, Kremer K, van Hijum SA, Siezen RJ, Borgdorff M, Bentley SD, Parkhill J, van Soolingen D. 2013. Inferring patient to patient transmission of Mycobacterium tuberculosis from whole genome sequencing data. BMC Infect Dis 13:110. http://dx.doi.org/10.1186/1471 -2334-13-110.
89. Pérez-Lago L, Comas I, Navarro Y, González-Candelas F, Herranz M, Bouza E, García-de-Viedma D. 2014. Whole genome sequencing analysis of intrapatient microevolution in Mycobacterium tuberculosis: potential impact on the inference of tuberculosis transmission. J Infect Dis 209:98-108. http://dx.doi.org/10.1093/infdis/jit439.
90. Rohde K, Yates RM, Purdy GE, Russell DG. 2007. Mycobacterium tuberculosis and the environment within the phagosome. Immunol Rev 219:37-54. http://dx.doi.org/10.1111/j.1600-065X.2007.00547.x.
91. O'Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MPR. 2013. The immune response in tuberculosis. Annu Rev Immunol 31:475-527. http://dx.doi.org/10.1146/annurev-immunol-032712-095939.
92. Galagan JE. 2014. Genomic insights into tuberculosis. Nat Rev Genet 15:307-320. http://dx.doi.org/10.1038/nrg3664.
93. Colangeli R, Arcus VL, Cursons RT, Ruthe A, Karalus N, Coley K, Manning SD, Kim S, Marchiano E, Alland D. 2014. Whole genome sequencing of Mycobacterium tuberculosis reveals slow growth and low mutation rates during latent infections in humans. PLoS One 9:e91024. http://dx.doi.org/10.1371/journal.pone.0091024.
94. Perdigão J, Silva H, Machado D, Macedo R, Maltez F, Silva C, Jordao L, Couto I, Mallard K, Coll F, Hill-Cawthorne GA, McNerney R, Pain A, Clark TG, Viveiros M, Portugal I. 2014. Unraveling Mycobacterium tuberculosis genomic diversity and evolution in Lisbon, Portugal, a highly drug resistant setting. BMC Genomics 15:991. http://dx.doi.org/10.1186 /1471-2164-15-991.
95. Huang Y-S, Chern H-D, Su W-J, Wu J-C, Lai S-L, Yang S-Y, Chang F-Y, Lee S-D. 2002. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35:883-889. http://dx.doi.org/10.1053/jhep.2002.32102.
96. Matsumoto T, Ohno M, Azuma J. 2014. Future of pharmacogeneticsbased therapy for tuberculosis. Pharmacogenomics 15:601-607. http: //dx.doi.org/10.2217/pgs.14.38.
97. Parkin DP, Vandenplas S, Botha FJ, Vandenplas ML, Seifart HI, van Helden PD, van der Walt BJ, Donald PR, van Jaarsveld PP. 1997. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis.AmJ Respir Crit Care Med 155:1717-1722. http: //dx.doi.org/10.1164/ajrccm.155.5.9154882.
98. Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R, Ito M, Yamamoto Y, Ogura T, Maeda K, Komuta K, Igarashi T, Azuma J. 2000. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 4:256-261.
99. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. 2002. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 166:916-919. http://dx.doi.org/10.1164/rccm.2108091.
100. Haiser HJ, Gootenberg DB, Chatman K, Sirasani G, Balskus EP, Turnbaugh PJ. 2013. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science 341:295-298. http://dx.doi.org/10.1126/science.1235872.
101. Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, Venkatesh M, Jobin C, Yeh L-A, Mani S, Redinbo MR. 2010. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330:831-835. http://dx.doi.org/10.1126/science.1191175.
102. Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK. 2009. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci USA106:14728-14733. http://dx.doi.org/10.1073/pnas.0904489106.
103. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung Y-M, Wu Y, Schauer P, Smith JD, Allayee H, Tang WHW, DiDonato JA, Lusis AJ, Hazen SL. 2011. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472:57-63. http://dx.doi.org/10.1038/nature09922.
104. Azad AK, Sadee W, Schlesinger LS. 2012. Innate immune gene polymorphisms in tuberculosis. Infect Immun 80:3343-3359. http://dx.doi .org/10.1128/IAI.00443-12.
105. Abel L, El-Baghdadi J, Bousfiha AA, Casanova J-L, Schurr E. 2014. Human genetics of tuberculosis: a long and winding road. Philos Trans R Soc Lond B Biol Sci 369:20130428. http://dx.doi.org/10.1098/rstb.2013 .0428.
106. Shaer O, Nov O. 2014. HCI for personal genomics. Interactions 21:32-37. http://dx.doi.org/10.1145/2656622.